188 related articles for article (PubMed ID: 27243809)
1. A Novel Phenanthridionone Based Scaffold As a Potential Inhibitor of the BRD2 Bromodomain: Crystal Structure of the Complex.
Tripathi S; Mathur S; Deshmukh P; Manjula R; Padmanabhan B
PLoS One; 2016; 11(5):e0156344. PubMed ID: 27243809
[TBL] [Abstract][Full Text] [Related]
2. Insights into the crystal structure of BRD2-BD2 - phenanthridinone complex and theoretical studies on phenanthridinone analogs.
Mathur S; Deshmukh P; Tripathi S; Marimuthu P; Padmanabhan B
J Biomol Struct Dyn; 2018 Jul; 36(9):2342-2360. PubMed ID: 28696179
[TBL] [Abstract][Full Text] [Related]
3. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
[TBL] [Abstract][Full Text] [Related]
4. Structural investigation of a pyrano-1,3-oxazine derivative and the phenanthridinone core moiety against BRD2 bromodomains.
Arole AH; Deshmukh P; Sridhar A; Padmanabhan B
Acta Crystallogr F Struct Biol Commun; 2022 Mar; 78(Pt 3):119-127. PubMed ID: 35234137
[TBL] [Abstract][Full Text] [Related]
5. Structural implications for K5/K12-di-acetylated histone H4 recognition by the second bromodomain of BRD2.
Umehara T; Nakamura Y; Wakamori M; Ozato K; Yokoyama S; Padmanabhan B
FEBS Lett; 2010 Sep; 584(18):3901-8. PubMed ID: 20709061
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of the human BRD2 bromodomain: insights into dimerization and recognition of acetylated histone H4.
Nakamura Y; Umehara T; Nakano K; Jang MK; Shirouzu M; Morita S; Uda-Tochio H; Hamana H; Terada T; Adachi N; Matsumoto T; Tanaka A; Horikoshi M; Ozato K; Padmanabhan B; Yokoyama S
J Biol Chem; 2007 Feb; 282(6):4193-201. PubMed ID: 17148447
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
9. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain.
Umehara T; Nakamura Y; Jang MK; Nakano K; Tanaka A; Ozato K; Padmanabhan B; Yokoyama S
J Biol Chem; 2010 Mar; 285(10):7610-8. PubMed ID: 20048151
[TBL] [Abstract][Full Text] [Related]
12. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
Chung CW; Coste H; White JH; Mirguet O; Wilde J; Gosmini RL; Delves C; Magny SM; Woodward R; Hughes SA; Boursier EV; Flynn H; Bouillot AM; Bamborough P; Brusq JM; Gellibert FJ; Jones EJ; Riou AM; Homes P; Martin SL; Uings IJ; Toum J; Clement CA; Boullay AB; Grimley RL; Blandel FM; Prinjha RK; Lee K; Kirilovsky J; Nicodeme E
J Med Chem; 2011 Jun; 54(11):3827-38. PubMed ID: 21568322
[TBL] [Abstract][Full Text] [Related]
14. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
Chen D; Lu T; Yan Z; Lu W; Zhou F; Lyu X; Xu B; Jiang H; Chen K; Luo C; Zhao Y
Eur J Med Chem; 2019 Nov; 182():111633. PubMed ID: 31461688
[TBL] [Abstract][Full Text] [Related]
15. Naphthyridines as novel BET family bromodomain inhibitors.
Mirguet O; Lamotte Y; Chung CW; Bamborough P; Delannée D; Bouillot A; Gellibert F; Krysa G; Lewis A; Witherington J; Huet P; Dudit Y; Trottet L; Nicodeme E
ChemMedChem; 2014 Mar; 9(3):580-9. PubMed ID: 24000170
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
17. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors.
Bharatham N; Slavish PJ; Shadrick WR; Young BM; Shelat AA
J Mol Graph Model; 2018 May; 81():197-210. PubMed ID: 29605436
[TBL] [Abstract][Full Text] [Related]
18. Novel pyrano 1,3 oxazine based ligand inhibits the epigenetic reader hBRD2 in glioblastoma.
Deshmukh P; Mathur S; Gangadharan G; Krishnappa G; Dalavaikodihalli Nanjaiah N; Padmanabhan B
Biochem J; 2020 Jun; 477(12):2263-2279. PubMed ID: 32484211
[TBL] [Abstract][Full Text] [Related]
19. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
20. Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails.
Liu Y; Wang X; Zhang J; Huang H; Ding B; Wu J; Shi Y
Biochemistry; 2008 Jun; 47(24):6403-17. PubMed ID: 18500820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]